Sodium-chloride symporter Inhibitors
1 drugsAbout Sodium-chloride symporter
The Sodium-chloride symporter (NCC or TSC) is a membrane protein in the kidneys responsible for reabsorbing sodium and chloride in the distal convoluted tubule. This process is critical for maintaining blood pressure and fluid balance.
The symporter is a therapeutic target in the cardiovascular area, though no genetic evidence currently links it to specific diseases. Targeting this symporter can modulate electrolyte reabsorption to manage hypertension.
One FDA-approved drug, EXFORGE HCT (Novartis), targets the Sodium-chloride symporter for cardiovascular indications. The drug is a small molecule approved in 2009.
Top Sodium-chloride symporter Drugs
Novartis is the only company with an approved drug targeting this symporter.
High market concentration suggests significant entry barriers or limited commercial opportunity.
Sodium-chloride symporter Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Sodium-chloride symporter, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Sodium-chloride symporter Clinical Trials 113 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Sodium-chloride symporter. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 23 | 20 | 1 | 2 | 95% |
| Phase 2 | 15 | 12 | 1 | 2 | 92% |
| Phase 3 | 29 | 22 | 5 | 2 | 81% |
| Phase 4 | 46 | 28 | 10 | 8 | 74% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Sodium-chloride symporter Drug Approval Timeline (2009 - 2009)
The first and only drug, EXFORGE HCT, was approved in 2009.
The approval timeline suggests a saturated market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 71 (28 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Sodium-chloride symporter. A trial counts if an approved drug acting on Sodium-chloride symporter is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.